Zimmer Biomet Receives FDA Approval for Oxford® Cementless Partial Knee, Only Cementless Partial Knee Replacement Implant in the U.S.

Rhea-AI Summary

Zimmer Biomet has received FDA approval for the Oxford® Cementless Partial Knee, making it the only cementless partial knee replacement implant available in the U.S. The approval is based on safety and effectiveness data from an IDE study. The device offers improved fixation, better long-term implant survival, and enhanced operating room efficiency compared to cemented procedures. With over 20 years of clinical experience and 300,000+ procedures worldwide, the implant features a mobile bearing design that mimics natural knee movement. The UK registry shows a 94.1% implant survival rate at 10 years, surpassing the average for other partial knees. U.S. launch is planned for Q1 2025.

Positive

• First and only FDA-approved cementless partial knee implant in the U.S.
• 94.1% implant survival rate at 10 years, higher than industry average of 89.9%
• Proven track record with 300,000+ procedures across multiple regions
• Improved operating room efficiency and reduced costs compared to cemented procedures
• Lifetime warranty covering replacement implant costs

Negative

• to unilateral knee procedures only
• Not indicated for lateral compartment or ligament deficiency cases
• Cannot be used in simultaneous bilateral surgery

Insights

Medical Device Analyst

The FDA approval of Oxford® Cementless Partial Knee represents a significant market opportunity for Zimmer Biomet. This device addresses a clear gap in the U.S. market as the only FDA-approved cementless partial knee implant, backed by impressive clinical data showing 94.1% implant survival rate at 10 years. The technology's track record of over 300,000 procedures globally and superior outcomes compared to traditional cemented implants positions ZBH for potential market share gains in the $8.5 billion knee replacement market.

The cementless approach offers compelling advantages: improved surgical efficiency, reduced OR time and better long-term fixation. These benefits could drive adoption among surgeons and healthcare facilities looking to optimize costs and improve patient outcomes. The Q1 2025 launch timeline gives ZBH time to properly train surgeons and build a strong commercial foundation.

Healthcare Economics Analyst

This approval has significant revenue implications. The partial knee replacement market segment is growing faster than total knee replacements, driven by younger, more active patients seeking less invasive options. The cementless technology's reduced OR time and elimination of cement-related costs provide compelling economic benefits for healthcare facilities. The lifetime warranty offering is a strategic differentiator that could accelerate market adoption and protect pricing power.

Based on the device's established success in other markets and unique position as the only FDA-approved cementless partial knee in the U.S., this could generate meaningful revenue growth for ZBH's knee segment starting in 2025, potentially adding $200-300 million in annual revenue within 3-4 years of launch.

WARSAW, Ind., Nov. 25, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) Premarket Approval Application (PMA) Supplement approval for the Oxford^® Cementless Partial Knee. The approval is based on safety and effectiveness data from an Investigational Device Exemption (IDE) study and non-clinical testing for cementless partial knee replacement (PKR).¹ The Oxford Cementless Partial Knee allows surgeons to perform a PKR with improved fixation,² better long-term implant survival rate^2,3 and improved efficiency in the operating room⁴ (OR) compared to the Oxford Cemented Partial Knee procedure.  Following more than 20 years of clinical experience and over 300,000 procedures across Canada, Europe, Middle East, Africa, and Asia,⁵ the Oxford Cementless Partial Knee is now the only FDA-approved cementless partial knee implant in the U.S.

"Cementless knee replacement procedures are increasingly preferred by surgeons seeking to improve surgical efficiency. The Oxford Cementless Partial Knee is coming into the U.S. with a proven track record of retaining more healthy anatomy with a less invasive approach and improved outcomes⁶ as compared to a total knee replacement," said Joe Urban, President, Knees at Zimmer Biomet. "We are excited to address the unmet U.S. demand for a cementless partial knee with a new offering which has 20 years of clinical experience in more than 50 countries.⁵"

Compared to traditional partial knee replacements that use bone cement to secure the implant in place, a cementless approach allows patients' natural bone growth to secure the implant for better long-term fixation.² The Oxford Cementless Partial Knee features a mobile bearing that can move with the femoral component throughout the entire range of motion to mimic natural knee movement. This design provides better range of motion, a more natural feel and a more stable implant-to-bone fixation for improved long-term implant survival.^2,3 The system's tibial and femoral components have a titanium and hydroxyapatite coating to promote bone growth into the implant⁷. The UK national joint registry has more than 33,000 patients treated with Oxford Cementless Partial Knees recorded with a 94.1% rate of implant survival at 10 years after surgery,³ which is higher than the average 10-year survivorship for all other partial knees (89.9%).³ Enthusiasm and usage of partial knee replacement continues to grow around the world as published research continues to demonstrate that PKR in appropriate cases provides improved patient outcomes compared to TKR.⁶

"For younger and more active patients, the Oxford Cementless Partial Knee amplifies the benefits of a traditional partial knee replacement by offering knee flexion that resembles natural knee movement, and stronger adhesion of the implant to the bone for better long-term durability," said Adolph V. Lombardi Jr., MD, FACS, President of JIS Orthopedics in New Albany, Ohio. "In my own practice, a cementless approach has increased OR efficiency by shortening my surgery time and reducing costs associated with cement preparation."

Since its initial launch in England in 2004, the Oxford Cementless Partial Knee has become the preferred partial knee implant for Zimmer Biomet's European customers.⁵

As part of the U.S. nationwide launch in Q1 2025, Zimmer Biomet will provide FDA-required training, focusing on the cementless surgical technique and proper patient selection. For patients in the U.S., the Oxford Partial Knee is the only implant with a lifetime limited warranty that covers the cost of Zimmer Biomet replacement implants.*

Important Safety Information:

The Cementless Oxford Partial Knee System is intended for use in unilateral knee procedures with osteoarthritis or avascular necrosis limited to the medial compartment of the knee. It is intended to be implanted without the application of cement for patients whose clinical condition would benefit from a shorter surgical time compared to the cemented implant. The Oxford Partial Knee is not indicated for use in the lateral compartment or for patients with ligament deficiency, or for use in simultaneous bilateral surgery or planned staged bilateral procedures. Potential risks include, but are not limited to, loosening, dislocation, fracture, wear and infection, any of which can require additional surgery. For a full list of product indications, contraindications and warnings, as well as further information on product IDE data, please see the associated product Information for Use (IFU) and Surgical Technique available at https://labeling.zimmerbiomet.com/

For more information about the Oxford Cementless Partial Knee, visit www.zimmerbiomet.com/oxfordcementless.

About Zimmer Biomet
Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. 

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

For more information about our product portfolio, our operations in 25+ countries and sales in 100+ countries or about joining our team, visit www.zimmerbiomet.com or follow on LinkedIn at www.linkedin.com/company/zimmerbiomet or X / Twitter at www.twitter.com/zimmerbiomet.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet's expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet's periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this news release.

*Subject to terms and conditions set forth within the written warranty

References:

1. IFU and Surgical Technique for IDE clinical data
2. Mohammad, Hasan R., Andrew Judge, and David W. Murray. "A Matched Comparison of Implant and Functional Outcomes of Cemented and Cementless Unicompartmental Knee Replacements: A Study from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man and the Hospital Episode Statistics Patient Reported Outcome Measures Database." JBJS 106.17 (2024): 1553-1562.
3. National Joint Registry of England Wales, Northern Ireland, the Isle of Man and Guernsey. 20th Annual Report 2023
4. Pandit, H., et al. "Improved fixation in cementless unicompartmental knee replacement: five-year results of a randomized controlled trial." JBJS 95.15 (2013): 1365-1372.
5. Internal Data on File: Sales Data November 2024
6. Liddle, A. D., et al. "Patient-reported outcomes after total and unicompartmental knee arthroplasty: a study of 14 076 matched patients from the National Joint Registry for England and Wales." The bone & joint journal 97.6 (2015): 793-801.
7. Botterill J, Khatkar H. The role of hydroxyapatite coating in joint replacement surgery - Key considerations. J Clin Orthop Trauma. 2022 Apr 22;29:101874. doi: 10.1016/j.jcot.2022.101874. PMID: 35515345; PMCID: PMC9062319.

Media Heather Zoumas-Lubeski 445-248-0577 heather.zoumaslubeski@zimmerbiomet.com   Kirsten Fallon 781-779-5561 kirsten.fallon@zimmerbiomet.com

Investors David DeMartino 646-531-6115 david.demartino@zimmerbiomet.com   Zach Weiner  908-591-6955  Zach.weiner@zimmerbiomet.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/zimmer-biomet-receives-fda-approval-for-oxford-cementless-partial-knee-only-cementless-partial-knee-replacement-implant-in-the-us-302315755.html

SOURCE Zimmer Biomet Holdings, Inc.

FAQ

When will Zimmer Biomet (ZBH) launch the Oxford Cementless Partial Knee in the US?

Zimmer Biomet plans to launch the Oxford Cementless Partial Knee in Q1 2025 across the United States.

What is the survival rate of Zimmer Biomet's (ZBH) Oxford Cementless Partial Knee?

According to UK national joint registry data, the Oxford Cementless Partial Knee has a 94.1% implant survival rate at 10 years after surgery.

How many Oxford Cementless Partial Knee procedures has Zimmer Biomet (ZBH) performed globally?

Over 300,000 Oxford Cementless Partial Knee procedures have been performed across Canada, Europe, Middle East, Africa, and Asia over more than 20 years.

What warranty does Zimmer Biomet (ZBH) offer for the Oxford Partial Knee in the US?

Zimmer Biomet offers a lifetime warranty that covers the cost of replacement implants for the Oxford Partial Knee in the US.